Medicaid Drug Utilization Review Board
Meeting Agenda
March 8, 2012

The Drug Utilization Review (DUR) Board will meet on March 8, 2012 from 9:00 a.m. to 4:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

Agenda Items

A. Drug Utilization Review

1. Selective Serotonin Reuptake Inhibitors/Serotonin-Norepinephrine Reuptake Inhibitors

   Drugs: Celexa, citalopram, Cymbalta, Effexor XR, Fluoxetine, fluoxetine weekly, fluvoxamine, Lexapro, Luvox CR, paroxetine, paroxetine CR, Paxil, Paxil CR, Pexeva, Pristiq, Prozac , Sarafem, Savella, sertraline, venlafaxine, venlafaxine ER, Viibryd, Zoloft

2. Long Acting Beta-Agonists

   Drugs: Arcapta, Brovana Inhalation Solution, Foradil Aerolizer, Foradil Certihaler, Perforomist Inhalation Solution, Serevent Diskus

3. Lubiprostone (Amitiza)

4. Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers/ Direct Renin Inhibitors and Related Combination Products

   Drugs: Accupril, Accuretic, Aceon, Altace, Amturnide, Atacand, Atacand HCT, Avalide, Avapro, Azor, benazepril, benazepril/amlopidine, benazepril /HCTZ, Benicar, Benicar HCT, captopril, captopril/HCTZ, Cozaar, Diovan, Diovan HCT, Edarbi, Edarbyclor, enalapril maleate, enalapril maleate/HCTZ, Exforge, Exforge HCT, fosinopril/HCTZ, fosinopril sodium, Hyzaar, lisinopril, lisinopril/HCTZ, losartan, losartan/HCTZ, Lotensin, Lotensin HCT, Lotrel, Mavik, Micardis, Micardis HCT, moexipril, moexipril/HCTZ, perindopril, Prinivil, Prinzide, quinapril, quinapril/HCTZ, ramipril, Tarka, Tekamlo, Tekturna, Tekturna HCT, Teveten, Teveten HCT, trandolapril, trandolapril/verapamil ER, Tribenzor, Twynsta, Uniretic, Univasc, Valturna, Vaseretic, Vasotec, Zestoretic, Zestril

5. Human Growth Hormone

   Drugs: Genotropin, Humatrope, Norditropin, Norditropin AQ, Nutropin, Omnitrope, Saizen, Tev-Tropin, Zorbtive

B. Program Updates

- PSYCKES
- Prescriber Education Program
- Pharmacy Claim System Enhancements

Please send me any corrections or comments. Please send me any corrections or comments.

Agenda Timeline (subject to change based on meeting proceedings)

9:00 - 9:45	Welcome and Introductions, Old Business
9:45 - 10:00	Public Comment Period*
10:00 - 11:00	Drug Utilization Review
11:00 - 11:45	Prescriber Education Program
11:45 - 12:30	PSYCKES
12:30 - 1:30	Lunch
1:30 - 3:00	Drug Utilization Review (continued)
3:00 - 3:30	Pharmacy Claims System Enhancements
3:30	Comments/Adjournment

*Interested parties must notify DOH at least one (1) week prior to the meeting of their request to address the DUR Board during the public comment period. Requests may be made by phone (518-486-3209) or e-mail (DUR@health.state.ny.us). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes.

All written statements must be received in an electronic format (DUR@health.state.ny.us) up to one (1) week in advance of the meeting. Written statements should summarize key points and may not exceed two (2) pages in length. If the submission of clinical information greater than two (2) pages in length is needed, the information must be received at least two (2) weeks prior to the meeting date or the Board may not have ample time to review the information. Please contact Department of Health (DOH) staff by e-mail (DUR@health.state.ny.us) prior to sending any information greater than two (2) pages.

Note: All information must be submitted to the DOH. Information should not be submitted directly to DUR Board members. DOH will ensure all information received (according to the guidelines above) is available for DUR Board review prior to the meeting.

Posted 02/10/2012